---
schema_version: "secwatch.filing_event.v1"
accession: "0001564590-21-057008"
form_type: "8-K"
ticker: "SPRB"
cik: "0001683553"
company_name: "SPRUCE BIOSCIENCES, INC."
filed_at: "2021-11-15T23:59:59+00:00"
generated_at: "2026-06-28T08:28:35.367231+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Spruce Q3 net loss $11.4M; CAHmelia-203 topline delayed to 2023; CEO retired

## Summary
- Net loss of $11.4M for Q3 2021; cash and investments $131.3M as of Sep 30.
- R&D expenses $8.6M (Q3 2021) vs $7.8M (Q3 2020); G&A $2.8M vs $1.8M.
- CAHmelia-203 topline results now expected in 2023 due to COVID-19 enrollment impact.
- Phase 2 trials in pediatric CAH and PCOS remain on track for initiation.
- CEO Richard King retired; Executive Chairman Mike Grey appointed Interim CEO.

## SEC filing metadata
- accession: 0001564590-21-057008
- form_type: 8-K
- ticker: SPRB
- cik: 0001683553
- company_name: SPRUCE BIOSCIENCES, INC.
- filed_at: 2021-11-15T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1683553/000156459021057008/0001564590-21-057008-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1683553/000156459021057008/sprb-8k_20211115.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001564590-21-057008
- JSON: https://secwatch.observer/filing/0001564590-21-057008.json
- Plain text: https://secwatch.observer/filing/0001564590-21-057008.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.